This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-histone IgG to IL12. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the histone as well as the biological activity of IL12. NHS-IL12 is a fusion protein comprising two IL12 heterodimers combined to the H-chain of an NHS76 monoclonal antibody. Murine in-vivo models have shown NHS-IL12 to be safe and efficacious with a subcutaneous route of administration showing the best results. The addition of the human IgG1 moiety resulted in a longer plasma half-life of NHS-IL12 than recombinant IL12, and a selective targeting to murine tumors in vivo. This immunocytokine was designed for treating necrotic tumor.
Figure 1 Anti-histone Antibody-Cytokine Fusion Protein, IgG-IL12 (ACFP-SH113) in ELISA
ELISA analysis of ACFP-SH113 was performed by coating with Histone H2A human.
The secondary antibody: HRP Goat Anti-human IgG
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH113. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.